
Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE
Drs Gutiérrez Junquera and Tzivinikos discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes.
Global experts Prof. Arjan Bredenoord and Drs. Ikuo Hirano, Kathryn Peterson, and Evan Dellon discuss identification and assessment of pediatric EoE.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.
Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.
This infographic examines the increased risk of low bone mineral density and impaired vertical growth observed in pediatric atopic dermatitis (AD). It also presents data demonstrating that dupilumab treatment is associated with improvements in growth compared to placebo and conventional systemic therapies in pediatric AD.

Join global experts Prof. Salvatore Oliva and Dr. Dhandapani Ashok for an educational symposium at ESPGHAN, as they discuss the burden and impact of underlying type 2 inflammation in eosinophilic esophagitis (EoE), and the importance of early diagnosis and management in pediatric patients.

Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.
In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.